Physician profile
Gretchen Abbott
NPI 1093533838
$4,449.93
in general payments reported to CMS, 2019-2025
40 companies · $3,533 in 2025
The $3,533 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $917 · 2025: $3,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,160 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,159.91 |
| Education | $290.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,005.89 | 2024-2025 | Rybrevant, Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $289.78 | 2024-2025 | |
| Daiichi Sankyo INC. | $262.03 | 2025 | Enhertu, Datroway, Vanflyta |
| Celgene Corporation | $215.27 | 2025 | Reblozyl, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $200.03 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.98 | 2024-2025 | Iclusig, Fruzaqla, Alunbrig |
| Sobi, INC | $190.68 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $162.62 | 2024-2025 | Keytruda, Reblozyl, Lynparza |
| Pfizer INC. | $142.02 | 2025 | |
| Astellas Pharma US INC | $128.11 | 2025 | Xtandi |
| Dendreon Pharmaceuticals LLC | $125.79 | 2024-2025 | Provenge |
| Glaxosmithkline, LLC. | $124.79 | 2025 | Ojjaara, Zejula, Jemperli |
| Lilly USA, LLC | $120.63 | 2025 | Jaypirca, Verzenio |
| Incyte Corporation | $116.55 | 2025 | Jakafi, Zynyz, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $95.16 | 2025 | Imfinzi, Calquence |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gretchen Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.